2017
Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT
Gao SJ, Kim AW, Puchalski JT, Bramley K, Detterbeck FC, Boffa DJ, Decker RH. Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT. Lung Cancer 2017, 109: 36-41. PMID: 28577947, DOI: 10.1016/j.lungcan.2017.04.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungClinical Decision-MakingDiagnostic ImagingFemaleHumansLung NeoplasmsMaleMediastinumMiddle AgedNeoplasm MetastasisNeoplasm StagingPatient SelectionPositron Emission Tomography Computed TomographyPractice Guidelines as TopicRetrospective StudiesConceptsOccult N2 diseaseOccult N2 metastasesGround-glass componentInvasive mediastinal stagingCurative-intent therapyT2 tumorsN2 metastasisPET-CTInvasive stagingN2 diseaseT1 tumorsNegative predictive valueMediastinal stagingEarly non-small cell lung cancerExact testPredictive valueSolid tumorsNon-small cell lung cancerClinical stage I NSCLCN2 lymph nodesNode-negative NSCLCOccult nodal involvementPure-solid tumorsStage I NSCLCT1-2N0 disease
2003
A Phase I Study of Gemcitabine and Docetaxel for Advanced Stage Solid Tumors
Poole ME, Bernard SA, Churchel MA, Weissler MC, Calvo B, Cance W, Ollila D, Koruda M, Behrns K, Detterbeck FC. A Phase I Study of Gemcitabine and Docetaxel for Advanced Stage Solid Tumors. Cancer Investigation 2003, 21: 350-354. PMID: 12901280, DOI: 10.1081/cnv-120018225.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityDose of docetaxelPhase IDay 1Solid tumorsAdvanced-stage solid tumorsSignificant nonhematologic toxicityPhase II studyRefractory solid tumorsPhase I studiesM2 i.Nonhematologic toxicityStable diseaseStarting doseII studyPartial responseHypersensitivity reactionsI studiesGastric cancerPrimary siteGemcitabinePatientsDocetaxelDoseConstant dose